Brief: Arecor Therapeutics Sees 2024 Revenue In Line With Consensus Market Expectations
10/06/2024 07:17
June 10 (Reuters) - Arecor Therapeutics PLC AREC.L :
* EXAMINING POTENTIAL COST MITIGATION IN NEAR TERM.
* EXPECTS THAT REVENUE FOR 2024 REMAINS IN LINE WITH
CONSENSUS
MARKET EXPECTATIONS
* IN ABSENCE OF SIGNIFICANT COST MITIGATION, FUNDING IS NOW
EXPECTED TO BE REQUIRED IN Q3 2024
Source text for Eikon: ID:nRSJ7052Ra
Further company coverage: AREC.L
((Reuters.Briefs@thomsonreuters.com;))